Do you want to read an article? Please log in or register.
Comparative cardiovascular safety of glucagon-like peptide-1 receptor agonists versus other antidiabetic drugs in routine care: a cohort study
Diabetes - GeneralType 2 Diabetes
Related content
Diabetes - GeneralType 2 DiabetesDiabetic Complications
Glucagon-Like Peptide-1 Receptor Agonists and the Risk of Incident Diabetic Retinopathy
Diabetes Care.
Douros A, Filion KB, Yin H, Yu OH, Etminan M, Udell JA, Azoulay L
doi: 10.2337/dc17-2280.
Type 2 Diabetes
Cardiovascular efficacy and safety of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: a systematic review and network meta-analysis
Diabet Med.
Hussein H, Zaccardi F, Khunti K, Seidu S, Davies MJ, Gray LJ
doi: 10.1111/dme.
COMMENTED
Further Publications
Comparative cardiovascular and renal effectiveness of sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide 1 receptor-agonists: Scandinavian cohort study
★ 1
Recommended and commented by
Prof. emer. Dr Ulrich Keller, Faculty Member
Diabetes Obes Metab
Ueda P, Wintzell V, Dahlqwist E, Eliasson B, Svensson AM, Franzén S, Gudbjörnsdottir S, Hveem K, Jonasson C, Melbye M, Hviid A, Svanström H, Pasternak B
doi: 10.1111/dom.14598
Type 2 Diabetes
Cardiovascular risk profiles: A cross-sectional study evaluating the generalisability of the glucagon-like peptide-1 receptor agonist cardiovascular outcome trials Rewind, Leader and Sustain-6 to the real-world type 2 diabetes population in the UK
Diabetes Obes Metab
Webb J, Mount J, von Arx LB, Rachman J, Spanopoulos D, Wood R, Tritton T, Massey O, Idris I
doi: 10.1111/dom.14580
COMMENTED
Type 2 Diabetes
Glycemic efficacy and safety of glucagon-like peptide-1 receptor agonist on top of sodium-glucose co-transporter-2 inhibitor treatment compared to sodium-glucose co-transporter-2 inhibitor alone: a systematic review and meta-analysis of randomized controlled trials
★ 1
Recommended and commented by
Prof. emer. Dr Ulrich Keller, Faculty Member
Diabetes Res Clin Pract.
Patoulias D, Stavropoulos K, Imprialos K, Katsimardou A, Kalogirou MS, Koutsampasopoulos K, Zografou I, Papadopoulos C, Karagiannis A, Doumas M
doi: 10.1016/j.diabres.2019.107927.
Type 2 DiabetesObesity and Bariatric Surgery
Glucagon-like peptide-1 receptor agonists and cardiovascular outcomes in patients with and without prior cardiovascular events: An updated meta-analysis and subgroup analysis of randomized controlled trials
Diabetes Obes Metab.
Mannucci E, Dicembrini I, Nreu B, Monami M
doi: 10.1111/dom.13888.
COMMENTED
Type 2 Diabetes
Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Co-Transporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Cardiovascular Outcomes Trials
Circulation.
Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Furtado RHM, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Bhatt DL, Leiter LA, McGuire DK,
Wilding JPH, Sabatine MS
doi: 10.1161/CIRCULATIONAHA.
Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies
BMC Cardiovasc Disord.
Li L, Li S, Liu J, Deng K, Busse JW, Vandvik PO, Wong E, Sohani ZN, Bala MM, Rios LP, Malaga G, Ebrahim S, Shen J, Zhang L, Zhao P, Chen Q, Wang Y, Guyatt GH, Sun X
doi: 10.1186/s12872-016-0260-0.
COMMENTED
Type 2 DiabetesGlycemic Control
Efficacy and Safety of Short- and Long-Acting Glucagon-Like Peptide 1 Receptor Agonists on a Background of Basal Insulin in Type 2 Diabetes: A Meta-analysis
★ 1
Recommended and commented by
Prof. emer. Dr Ulrich Keller, Faculty Member
Diabetes Care
Huthmacher JA, Meier JJ, Nauck MA
doi: 10.2337/dc20-0498